Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avandia 90% Formulary Acceptance Achieved At One Month Post-Launch - SB

Executive Summary

SmithKline Beecham/Bristol-Myers Squibb's Avandia has been "very quickly embraced" by managed care and is reimbursed by 90% of plans, SmithKline Beecham Chief Operating Officer Jean-Pierre Garnier, PhD, reported Sept. 16 at the Bear Stearns health care conference in New York City.

You may also be interested in...



SmithKline Avandia Recommended Only For Combination Use By CPMP

SmithKline Beecham's thiazolidinedione antidiabetic Avandia is in the final stages of EU approval following a positive recommendation by the Committee for Proprietary Medicinal Products March 16.

SmithKline Avandia Recommended Only For Combination Use By CPMP

SmithKline Beecham's thiazolidinedione antidiabetic Avandia is in the final stages of EU approval following a positive recommendation by the Committee for Proprietary Medicinal Products March 16.

HMR's Arava May Be Ripe For Review By Cigna Soon After 6-Month Delay

Hoechst Marion Roussel's arthritis immunotherapy Arava is likely to be considered for coverage by the large Cigna Healthcare prescription plan, which represents about 1% of total U.S annual drug purchases.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS034865

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel